First CRISPR Genome Editing and Initiation of Clinical Trials
In China, on October 28, the first patient treatment with CRISPR genome editing for lung cancer was performed by removing immune cells, editing them to engender heightened immune function (disabling PD-1), culturing the cells, and injecting them back into the patient. More trials have been approved to start in the United States for cancer and there has been remarkable progress for a variety of monogenic diseases, such as sickle cell, with clinical trials to start soon ( Table ).
Medscape © 2016 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Eric J. Topol. 10 Tech Advances That Can Change Medicine - Medscape - Dec 16, 2016.